Related Experiment Video
Updated: May 10, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Using genetic testing to guide therapeutic decisions in cardiomyopathy
1Brigham and Women's Hospital, Division of Cardiovascular Medicine, VA Boston Health Care, Harvard Medical School, Boston, MA. 75 Francis Street, Boston, MA, 02115, USA, nlakdawala@partners.org.
Current Treatment Options in Cardiovascular Medicine
|June 25, 2013
Summary
Genetic testing for cardiomyopathy is now a clinical tool, aiding family evaluations and diagnosing unclear cases. Careful DNA interpretation is key for future preventative therapies in high-risk individuals.
Area of Science:
- Cardiovascular genetics
- Clinical diagnostics
- Human genomics
Background:
- Genetic analysis for human cardiomyopathy has evolved from research to clinical application.
- Genetic testing enhances efficiency in evaluating families and clarifying ambiguous clinical presentations.
Purpose of the Study:
- To highlight the diagnostic utility of genetic testing in cardiomyopathy.
- To emphasize the role of genetic diagnosis in enabling preventative therapies.
- To underscore the importance of expert interpretation of genetic variations.
Main Methods:
- Not applicable (Opinion Statement)
Main Results:
- Not applicable (Opinion Statement)
Conclusions:
- Genetic testing is a valuable diagnostic tool for cardiomyopathy.
- Preventative strategies based on genetic diagnosis are under investigation.
- Specialized cardiovascular genetics clinics are crucial for accurate DNA sequence variation interpretation.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...